The Latest Cardiac and Vascular News
Acquisition adds next-generation CLAAS® AcuFORM™ Technology to Gore’s portfolio CAUTION: Investigational Device. Limited by federal (or United States) law to investigational use. Outside the United States, the device is intended exclusively for clinical investigation. Not approved for commercial use. NEWARK, Del., Jan. 5, 2026 /PRNewswire/ — W. L. Gore & Associates, Inc. (Gore) […]
The GORE® VIABAHN® FORTEGRA Venous Stent is engineered to offer an optimal balance of conformability and compression resistance for treating a broad range of patients. FLAGSTAFF, Ariz., Jan. 6, 2026 /PRNewswire/ — W. L. Gore & Associates’ medical business (Gore) has announced the FDA…
The investigational device evaluated in the trial, previously known as the GORE® VIAFORT Vascular Stent, will now be referred to as the GORE® VIABAHN® FORTEGRA Venous Stent. CAUTION: Investigational device. Limited by United States law to investigational use. LAS VEGAS and FLAGSTAFF, Ariz….
The GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis indication expansion brings the first bridging stent device with dual indication for both fenestrated and branched endovascular repair*. PUTZBRUNN, Germany, July 9, 2025 /PRNewswire/ — W. L. Gore & Associates (Gore) announces CE…
CAUTION: Investigational device. Limited by United States law to investigational use. FIRST U.S. PATIENT ENROLLED IN GORE® VIAFORT Vascular Stent ILIOFEMORAL pivotal study FLAGSTAFF, Ariz., June 6, 2023 /PRNewswire/ — W. L. Gore & Associates (Gore) has announced that the first U.S. patient has been enrolled in a prospective, non-randomized, multicenter, single-arm study with five-year follow-up […]
CAUTION: Investigational device. Limited by United States law to investigational use. FIRST U.S. PATIENT ENROLLED IN GORE® VIAFORT Vascular Stent pivotal study FLAGSTAFF, Ariz., March 28, 2023 /PRNewswire/ — W. L. Gore & Associates (Gore) has announced that the first U.S. patient has been enrolled in a prospective, non-randomized, multicenter, single-arm study with 5-year […]
CAUTION: Investigational device. Limited by United States law to investigational use. W. L. Gore & Associates initiates its GORE® VIAFORT Device Pivotal Clinical Study for the treatment of inferior vena cava occlusive disease. FLAGSTAFF, Ariz., Oct. 28, 2022 /PRNewswire/ — W. L. Gore & Associates (Gore) today announced the first implants of its investigational GORE® VIAFORT Vascular […]
This registry will confirm safety and performance of the VBX Stent Graft in peripheral vessels in patients who require interventional treatment in a variety of applications and diseases. PUTZBRUNN, Germany, Oct. 27, 2022 /PRNewswire/ — W. L. Gore & Associates, Inc. (Gore) announced the completion of target enrollment in the EXPAND Post-Market Registry […]
FLAGSTAFF, Ariz., Aug. 19, 2021 /PRNewswire/ — W. L. Gore & Associates (Gore), today announced that five-year results of the U.S. prospective, multicenter study (N = 63) of endovascular repair of iliac aneurysms using the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE) were presented at the 2021 Society for Vascular Surgery Annual Meeting. Results of the […]
– Published in the New England Journal of Medicine (NEJM), the REDUCE Study continues to show the largest reduction in recurrent ischemic stroke in all PFO shunt sizes over medical therapy alone.*,¹ – Long-term results highlight GORE® CARDIOFORM Septal Occluder can be trusted for patient safety and effective defect closure. FLAGSTAFF, Ariz., March […]
